全文获取类型
收费全文 | 691篇 |
免费 | 84篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 24篇 |
妇产科学 | 39篇 |
基础医学 | 145篇 |
口腔科学 | 23篇 |
临床医学 | 135篇 |
内科学 | 88篇 |
皮肤病学 | 34篇 |
神经病学 | 20篇 |
特种医学 | 29篇 |
外科学 | 64篇 |
综合类 | 59篇 |
一般理论 | 1篇 |
预防医学 | 53篇 |
药学 | 43篇 |
肿瘤学 | 17篇 |
出版年
2022年 | 8篇 |
2021年 | 17篇 |
2020年 | 10篇 |
2019年 | 11篇 |
2018年 | 26篇 |
2017年 | 6篇 |
2016年 | 4篇 |
2015年 | 12篇 |
2014年 | 17篇 |
2013年 | 35篇 |
2012年 | 16篇 |
2011年 | 30篇 |
2010年 | 17篇 |
2009年 | 11篇 |
2008年 | 21篇 |
2007年 | 19篇 |
2006年 | 21篇 |
2005年 | 21篇 |
2004年 | 22篇 |
2003年 | 21篇 |
2002年 | 21篇 |
2001年 | 37篇 |
2000年 | 31篇 |
1999年 | 43篇 |
1998年 | 12篇 |
1997年 | 7篇 |
1996年 | 3篇 |
1995年 | 7篇 |
1994年 | 6篇 |
1993年 | 6篇 |
1992年 | 26篇 |
1991年 | 19篇 |
1990年 | 11篇 |
1989年 | 21篇 |
1988年 | 24篇 |
1987年 | 14篇 |
1986年 | 12篇 |
1985年 | 33篇 |
1984年 | 14篇 |
1983年 | 5篇 |
1982年 | 4篇 |
1980年 | 5篇 |
1979年 | 3篇 |
1978年 | 9篇 |
1977年 | 8篇 |
1975年 | 2篇 |
1974年 | 8篇 |
1973年 | 9篇 |
1972年 | 15篇 |
1971年 | 3篇 |
排序方式: 共有776条查询结果,搜索用时 15 毫秒
81.
Panerai RB Hudson V Fan L Mahony P Yeoman PM Hope T Evans DH 《Physiological measurement》2002,23(1):59-72
Assessments of dynamic cerebral autoregulation usually measure the cerebral blood flow velocity (CBFV) response to changes in arterial blood pressure (ABP). We studied the effect of substituting ABP by cerebral perfusion pressure (CPP), expressed as the difference between ABP and intracranial pressure (ICP), in estimates of dynamic autoregulation obtained by transfer function analysis. CBFV, ABP and ICP were recorded during periods of physiological stability in 30 patients with severe head injury. Transfer function analysis was performed using the following combinations of input-output variables: ABP-CBFV, CPP-CBFV and CBFV-ICP. Frequency and time-domain (step response) functions were averaged for recordings with mean ICP < 20 mmHg (group A) and mean ICP > or = 20 mmHg (group B). The ABP-CBFV transfer function parameters and step response for group A were similar to previous studies in normal subjects, but group B showed deterioration of dynamic autoregulation. Radically different step responses were obtained from both groups for the CPP-CBFV transfer function and the coherence was not significantly improved. The CBFV-ICP transfer function had the highest values of coherence and indicates that changes in CBFV are the cause of spontaneous fluctuations in ICP. Furthermore, the ICP step response plateau was significantly higher for group B than for group A. An alternative calculation of the CBFV step response to changes in CPP resembled the corresponding responses for the ABP input. For spontaneous fluctuations in ABP, ICP and CBFV, it is not possible to calculate the CPP-CBFV transfer function directly due to the high positive correlation between ICP and CBFV, but an alternative estimate can be obtained by using the CBFV-ICP transfer function. The latter could also be useful as a method to assess intracranial compliance in head injury patients. 相似文献
82.
Caroline Codling Liam O’Mahony Fergus Shanahan Eamonn M. M. Quigley Julian R. Marchesi 《Digestive diseases and sciences》2010,55(2):392-397
Purpose
The objectives of this study were, firstly, to determine the diversity of the host’s gut microbiota in irritable bowel syndrome (IBS) using a culture-independent method (DGGE of the 16S rRNA gene) and, secondly, to examine mucosal biopsies of IBS patients and compare them to their own fecal microbiota. 相似文献83.
Luinstra K Petrich A Castriciano S Ackerman M Chong S Carruthers S Ammons B Mahony JB Smieja M 《Journal of clinical microbiology》2011,49(6):2138-2142
The clinical and public health importance of influenza and other respiratory viruses has accelerated the development of highly sensitive molecular diagnostics, but data are limited regarding preanalytical stages of diagnostic testing. We evaluated CyMol, an alcohol-based transport medium, for its ability to maintain specimen integrity for up to 21 days of storage at various temperatures; for its ability to inactivate virus; and for its compatibility with antigen- or nucleic acid-based diagnostics for respiratory viruses in clinical samples. In mock-infected samples, both universal transport medium (UTM-RT) and CyMol maintained equivalent viral quantities for at least 14 days at room temperature or colder, whereas a dry swab collection maintained viral quantities only if refrigerated or frozen. CyMol inactivated influenza virus within 5 min of sample immersion. UTM-RT- and CyMol-collected nasal swab specimens from 73 symptomatic students attending a campus health clinic were positive for a respiratory virus in 56.2% of subjects by multiplex PCR testing, including influenza A and B viruses, rhinovirus/enteroviruses, coronaviruses, respiratory syncytial virus, parainfluenza viruses, metapneumovirus, and adenovirus. Detection by PCR was equivalent in UTM-RT- and CyMol-collected specimens and in self- and staff-collected swabs. Direct fluorescent antibody (DFA) testing was substantially less sensitive (23.3%) than multiplex PCR, and DFA testing from UTM-RT-collected swabs was more sensitive than that from CyMol-collected swabs. These data indicate that an alcohol-based transport medium such as CyMol preserves respiratory virus integrity, rapidly inactivates viruses, and is compatible with PCR-based respiratory diagnostics. 相似文献
84.
Ryan F. Donnelly Thakur Raghu Raj Singh Michael M. Tunney Desmond I. J. Morrow Paul A. McCarron Conor O’Mahony A. David Woolfson 《Pharmaceutical research》2009,26(11):2513-2522
Methods
In this study we determined, for the first time, the ability of microorganisms to traverse microneedle-induced holes using two different in vitro models. 相似文献85.
Ohye RG Gaynor JW Ghanayem NS Goldberg CS Laussen PC Frommelt PC Newburger JW Pearson GD Tabbutt S Wernovsky G Wruck LM Atz AM Colan SD Jaggers J McCrindle BW Prakash A Puchalski MD Sleeper LA Stylianou MP Mahony L;Pediatric Heart Network Investigators 《The Journal of thoracic and cardiovascular surgery》2008,136(4):968-975
86.
Dendritic cell discoveries provide new insight into the cellular immunobiology of DNA vaccines. 总被引:19,自引:0,他引:19
The evolution of increasingly virulent human pathogens, together with the rapid onset of antimicrobial resistance has created a need for new vaccination strategies. Nucleic acid vaccines, based on recombinant DNA technology are a promising new vaccine formulation capable of eliciting both humoral and cellular immune responses. This technology has been experimentally validated in animal models of pathogen challenge and tumor protection following administration of a DNA vaccine and has led to extensive research into the mechanisms of protective immunity. We focus here on the cellular and molecular mechanisms leading to cell-mediated immune responses to DNA vaccines and discuss these mechanisms in light of recent advances in the field of dendritic cell immunobiology. In particular, the potential involvement of: (i) the CpG pattern-recognition receptor, toll-like receptor-9; (ii) the dendritic cell-specific surface adhesion molecule, DC-SIGN; and (iii) the molecular interactions between CD40 and CD154 in the evolution of protective cell-mediated immunity to DNA vaccines are discussed. An improved understanding of the precise mechanisms leading to protective cellular immunity following DNA vaccination may help in the design of novel DNA constructs containing immunostimulatory features that target one or more of these mechanisms, with the aim of increasing the immunogenic potential and protective efficacy of DNA vaccines. 相似文献
87.
88.
89.
P J Mahony 《The American journal of psychiatry》1990,147(8):1109-1110
90.
Carvedilol for children and adolescents with heart failure: a randomized controlled trial 总被引:4,自引:0,他引:4
Shaddy RE Boucek MM Hsu DT Boucek RJ Canter CE Mahony L Ross RD Pahl E Blume ED Dodd DA Rosenthal DN Burr J LaSalle B Holubkov R Lukas MA Tani LY;Pediatric Carvedilol Study Group 《JAMA》2007,298(10):1171-1179
Context Although -blockers improve symptoms and survival in adults with heart failure, little is known about these medications in children and adolescents. Objective To prospectively evaluate the effects of carvedilol in children and adolescents with symptomatic systemic ventricular systolic dysfunction. Design, Setting, and Participants A multicenter, randomized, double-blind, placebo-controlled study of 161 children and adolescents with symptomatic systolic heart failure from 26 US centers. In addition to treatment with conventional heart failure medications, patients were assigned to receive placebo or carvedilol. Enrollment began in June 2000 and the last dose was given in May 2005 (each patient received medication for 8 months). Interventions Patients were randomized in a 1:1:1 ratio to twice-daily dosing with placebo, low-dose carvedilol (0.2 mg/kg per dose if weight <62.5 kg or 12.5 mg per dose if weight 62.5 kg), or high-dose carvedilol (0.4 mg/kg per dose if weight <62.5 kg or 25 mg per dose if weight 62.5 kg) and were stratified according to whether each patient's systemic ventricle was a left ventricle or not. Main Outcome Measures The primary outcome was a composite measure of heart failure outcomes in patients receiving carvedilol (low- and high-dose combined) vs placebo. Secondary efficacy variables included individual components of this composite, echocardiographic measures, and plasma b-type natriuretic peptide levels. Results There was no statistically significant difference between groups for the composite end point based on the percentage of patients who improved, worsened, or were unchanged. Among 54 patients assigned to placebo, 30 improved (56%), 16 worsened (30%), and 8 were unchanged (15%); among 103 patients assigned to carvedilol, 58 improved (56%), 25 worsened (24%), and 20 were unchanged (19%). The rates of worsening were lower than expected. The odds ratio for worsened outcome for patients in the combined carvedilol group vs the placebo group was 0.79 (95% CI, 0.36-1.59; P = .47). A prespecified subgroup analysis noted significant interaction between treatment and ventricular morphology (P = .02), indicating a possible differential effect of treatment between patients with a systemic left ventricle (beneficial trend) and those whose systemic ventricle was not a left ventricle (nonbeneficial trend). Conclusions These preliminary results suggest that carvedilol does not significantly improve clinical heart failure outcomes in children and adolescents with symptomatic systolic heart failure. However, given the lower than expected event rates, the trial may have been underpowered. There may be a differential effect of carvedilol in children and adolescents based on ventricular morphology. Trial Registration clinicaltrials.gov Identifier: NCT00052026 相似文献